Company: VERA
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0001140361-25-012034
Chunk: 62

Company: Vera Therapeutics, Inc.
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 62
---
 grant-date fair value of not more than $400,000, on the date of each of our annual stockholder meetings, for non-employee directors who joined our Board no later than February 28 of the year in which the stockholders meeting is held. |

The grants made to non-employee directors in 2024 were made pursuant to this policy. On December 9, 2024, the Board further amended the non-employee director compensation policy, which became effective January 1, 2025, to increase certain annual cash retainers (each of which are in addition to the annual cash retainer of $40,000 for service as member of the Board), as set forth below:

| • | the Chair Retainer was increased to $35,000; |

| • | the Committee Member Retainer for service as a member of the Compensation Committee was increased to $7,500; and |

| • | the Committee Chair Retainer for service as chair of the Compensation Committee was increased to $7,500. |

Each of the option grants described above will be granted under our 2021 Plan. Each initial option grant will vest monthly over a three-year period subject to the director’s continuous service to us. Each annual option grant will vest subject to the director’s continuous service to us through the earlier of the first anniversary of the date of grant or the next annual stockholder meeting. Notwithstanding the foregoing, in the event there is a change in control (as defined in the 2021 Plan) all of the option grants will accelerate and become fully vested subject to such non-employee director’s continuous service with us through such change in control. The term of each option will be 10 years, subject to earlier termination as provided in the 2021 Plan.

42

TABLE OF CONTENTS

TRANSACTIONS WITH RELATED PERSONS AND INDEMNIFICATION The following includes a summary of transactions during the last two completed fiscal years to which we have been a party in which the amount involved exceeded or will exceed the lesser of $120,000 or 1% of our total assets as of our last two completed fiscal years, and in which any of our directors, director nominees, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under “Executive Compensation